PRESS RELEASES

• Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit

  November 1, 2019
• Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study

  October 31, 2019
• Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

  January 17, 2019
• Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting

  December 5, 2018